These NCCN Guidelines Insights highlight the important updates/changes specific to the 2016 version of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma.

NCCN Evidence Blocks™ are intended as a visual representation of five key measures that provide important information about specific recommendations contained within the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).

This information was originally presented at the NCCN 10^th Annual Congress: Hematologic Malignancies™ held in San Francisco, California.

This information was originally presented at the NCCN 10^th Annual Congress: Hematologic Malignancies™ held in San Francisco, California.

Immune therapy has emerged as a promising area of cancer therapeutics based on its potential for tumor selectivity and targeting of chemotherapy-resistant clones. Allogeneic transplantation produces durable remissions in a subset of patients, albeit at the cost of graft-versus-host disease.

Join Kenneth Anderson, MD and Paul Richardson, MD as they present their multidisciplinary expertise on a range of cases pertaining to multiple myeloma.

This information was originally presented at the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.

Join Kenneth Anderson, MD and Paul Richardson, MD as they present their multidisciplinary expertise on a range of cases pertaining to multiple myeloma.

This information was originally presented on September 20, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.

This information was originally presented on September 20, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.